Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration or FDA has accepted the company's New Drug Application or NDA and granted Priority Review for alectinib, an oral investigational anaplastic lymphoma kinase or ALK inhibitor, for the treatment of people with ALK-positive, locally advanced or metastatic non-small cell lung cancer or NSCLC who have progressed on or are intolerant to crizotinib.
Alectinib was granted Breakthrough Therapy Designation by the FDA in June 2013 for people with ALK-positive NSCLC whose disease progressed on crizotinib...
Roche seems to be on a roll with Esbriet for respriratory illnesses, atezolizumab as a new cancer drug, and what appears to be a new blockbuster, ocrelizumab for multiple sclerosis. Interesting to see what is reported next week at ECTRIMS... European Committee for Treatment and Research in Multiple Sclerosis on Phase 3 trials of ocrelizumab.
Why is the volume so low on this stock? I am considering buying shares but I couldn't trade in the pre-market.
It seems they have alot in the pipeline and are now doing an acquisition..
thoughts from existing shareholders?
This MB is not active.
Stop randomly guessing what stocks are going to go up. I get my biggest OTCMarket, NASDAQ and NYSE winners from the experts at PennyStock101 (org). Google them and sign up to their newsletter right now. It's awesome.
BIG reorg last week, with early retirement at the top of the tissue biz (tissue rolled up into molecular and sequencing). Pot has been stirred enough to spur additional departures, no doubt. Yet to be seen if the dead wood will truly be pruned, or whether typical Roche MO continues of simply waiting for the dead wood to fall off the "naturally"....which is never good for the tree.